LMLL.F Stock Overview
Operates as a specialty pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pharmadrug Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.058 |
| 52 Week Low | CA$0.0042 |
| Beta | 2.69 |
| 11 Month Change | -43.50% |
| 3 Month Change | -42.56% |
| 1 Year Change | -69.85% |
| 33 Year Change | -95.08% |
| 5 Year Change | -94.40% |
| Change since IPO | -99.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| LMLL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -17.9% | 1.6% | 2.2% |
| 1Y | -69.9% | 9.9% | 31.6% |
Return vs Industry: LMLL.F underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: LMLL.F underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| LMLL.F volatility | |
|---|---|
| LMLL.F Average Weekly Movement | 38.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LMLL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LMLL.F's weekly volatility has decreased from 44% to 38% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Robert Steen | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Pharmadrug Inc. Fundamentals Summary
| LMLL.F fundamental statistics | |
|---|---|
| Market cap | US$1.16m |
| Earnings (TTM) | -US$9.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs LMLL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMLL.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$13.17m |
| Earnings | -CA$13.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -107.3% |
How did LMLL.F perform over the long term?
See historical performance and comparison